Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 560 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 560 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $95.71, for a total transaction of $53,597.60. Following the transaction, the senior vice president owned 14,752 shares of the company’s stock, valued at approximately $1,411,913.92. The trade was a 3.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

• On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $92.23, for a total transaction of $872,403.57.
• On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00.
• On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $84.63, for a total transaction of $846,215.37.
• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The stock was sold at an average price of $80.95, for a total value of $128,467.65.

Oruka Therapeutics Trading Down 3.9%

ORKA stock opened at $92.20 on Wednesday. The stock has a 50-day moving average price of $95.87 and a 200-day moving average price of $72.78. Oruka Therapeutics, Inc. has a 1-year low of $14.66 and a 1-year high of $115.51. The firm has a market cap of $6.10 billion, a PE ratio of -45.42 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, analysts forecast that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current year.

Institutional Trading of Oruka Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in Oruka Therapeutics in the second quarter worth approximately $474,916,000. Jupiter Topco LLC bought a new stake in shares of Oruka Therapeutics during the second quarter valued at approximately $130,968,000. Remedium Capital Partners LLC increased its holdings in shares of Oruka Therapeutics by 0.9% during the first quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock valued at $76,796,000 after acquiring an additional 13,247 shares in the last quarter. Perceptive Advisors LLC raised its position in shares of Oruka Therapeutics by 16.4% during the fourth quarter. Perceptive Advisors LLC now owns 1,476,501 shares of the company’s stock worth $44,753,000 after purchasing an additional 208,480 shares during the period. Finally, Avidity Partners Management LP raised its position in shares of Oruka Therapeutics by 15.1% during the first quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock worth $37,299,000 after purchasing an additional 100,000 shares during the period. 56.44% of the stock is owned by institutional investors.

Oruka Therapeutics News Roundup

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Analysts remain broadly optimistic about Oruka’s pipeline. Ten analysts rate the stock a Buy, compared with one Sell rating, and the consensus price target is $133, well above the recent trading range. BTIG, Wedbush, Mizuho and HC Wainwright have maintained favorable ratings or price targets ranging from $120 to $165. Oruka analyst ratings and price targets
• Positive Sentiment: The EVERLAST-A 28-plus-week data for ORKA-001 in psoriasis is being highlighted as a key upcoming catalyst. Positive durability or efficacy results could strengthen the investment case for Oruka’s long-acting antibody platform. EVERLAST-A data catalyst article
• Neutral Sentiment: Recent insider sales were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. CEO Lawrence Klein sold 2,452 shares, SVP Arjun Agarwal sold 10,019 shares across two transactions, and Joana Goncalves sold 7,947 shares. Because the transactions were tax-related and planned in advance, they are less informative than discretionary sales, although they may still attract investor attention. Oruka insider sales report
• Negative Sentiment: Oruka remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss of $0.55 per share exceeded the expected $0.51 loss, and analysts expect a full-year loss of approximately $2.42 per share. The stock is also trading below its 50-day moving average, underscoring sensitivity to clinical updates and financing concerns.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ORKA shares. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Guggenheim reiterated a “buy” rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Piper Sandler reiterated an “overweight” rating and set a $180.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Wedbush reiterated an “outperform” rating and set a $165.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Finally, HC Wainwright reissued a “buy” rating and set a $120.00 target price on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Oruka Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $133.00.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.